Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 23/08/2022
• Auteurs : Geoffrey AvisYann GricourtPierre Baptiste VialatteVictor MeunierMikael PerinNatacha SimonPierre-Geraud ClaretHassan El FertitJean-Yves LefrantMartin M. BertrandPhilippe Cuvillon
• Organismes : Centre Hospitalier Universitaire de Nîmes Université de Montpellier Centre Hospitalier Universitaire de Nîmes Université de Montpellier Centre Hospitalier Universitaire de Nîmes Université de Montpellier Centre Hospitalier Universitaire de Nîmes Université de Montpellier Centre Hospitalier Universitaire de Nîmes Université de Montpellier Centre Hospitalier Universitaire de Nîmes Hôpital Universitaire Carémeau [Nîmes] Centre Hospitalier Universitaire de Nîmes Unité de réanimation médicale [CHU de Carémeau, Nîmes] Initial MAnagement and prevention of acute orGan failures IN critically ill patiEnts Centre Hospitalier Universitaire de Nîmes Initial MAnagement and prevention of acute orGan failures IN critically ill patiEnts Centre Hospitalier Universitaire de Nîmes Initial MAnagement and prevention of acute orGan failures IN critically ill patiEnts
• Publié dans Regional Anesthesia and Pain Medicine le 28/10/2020

---

Résumé : Introduction: Erector spinae plane block has been proposed to reduce opioid use and improve pain relief with controversial results. This randomized clinical study aimed to assess the efficacy of erector spinae plane block in major spine surgery including multimodal and 'Enhance Recovery After Surgery' programs. Method: After institutional review board approval, adult patients undergoing elective lumbar spine surgery with standardized general anesthesia, rehabilitation and multimodal analgesia protocols were randomly allocated to receive bilateral ultrasound-guided block with saline versus ropivacaine (3.75 mg/mL). Before surgery, a bilateral erector spinae plane block was performed at lumbar level (third vertebrae) with 20 mL of solution for each side. The primary outcome was morphine consumption after 24 hours. Secondary outcomes included pain scores and side effects, from postanesthesia care unit to discharge, and questionnaires at 3 months on pain and quality of life (EQ-5D). Results: From November 2019 to July 2021, 50 patients were enrolled with similar characteristics and surgery for each group. After the first 24 hours, there was no statistical difference regarding cumulative intravenous morphine consumption between ropivacaine and saline groups: 7.3 mg (3.7-19) vs 12.5 mg (3.5-26) (p=0.51). Over the five postoperative days, opioid sparing, pain scores and side effects were similar between groups. At 3 months, pain relief, incidence of chronic pain and EQ-5D were similar between groups. Discussion: Erector spinae plane block used in conjunction with 'Enhance Recovery After Surgery' and multimodal analgesia protocols provides limited reduction in opioid consumption and no long-term benefits. Trial registration number: EudraCT 2019-001678-26.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 20/08/2022
• Auteurs : Thomas SchmitzMuriel Doret-DionLoic SentilhesOlivier ParantOlivier ClarisLaurent RenesmeJulie AbbalAude GiraultHéloïse TorchinMarie HoullierNolwenn Le SachéAlexandre VivantiDaniele de LucaNorbert WinerCyril FlamantClaire ThuillierPascal BoileauJulie BlancVéronique BrevautPierre-Emmanuel BouetGéraldine GascoinGaël BeucherValérie Datin-DorriereStéphane BounanPascal BolotChristophe PonceletCorinne AlbertiMoreno UrsinoCamille AupiaisOlivier BaudPhilippe BoizeCharles GarabédianFlorence FlameinMaela Le LousAlain BeuchéeJean GondryPierre TourneuxPerrine Coste-MazeauAntoine BeduDenis GallotKaren CosteCéline ChauleurHugues PaturalGilles KayemDelphine MitanchezHélène HeckenrothFarid BoubredJeanne SibiudeLuc DesfrèreCaroline BohecThierry MansirAntoine KochPierre KuhnNadia TilloucheFabrice LapeyreFranck PerrotinGéraldine FavraisEdouard LecarpentierXaxier DurrmeyerVéronique EquyThierry DebillonLuc RigonnotStéphanie LefoulgocClaudia BrieAnne-Sophie PagèsRomy RayssiguierGilles CambonieCorinne CudevilleDoriane MadeleneauOlivier MorelJean-Michel HascoetVincent LetouzeyMassimo Di MaioLaurent SalomonAlexandre Lapillonne
• Organismes : Hôpital Robert Debré Hôpital Femme Mère Enfant [CHU - HCL] Centre Hospitalier Universitaire de Bordeaux Centre Hospitalier Universitaire de Toulouse Hospices Civils de Lyon Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] Centre Hospitalier Universitaire de Toulouse Maternité Port-Royal [CHU Cochin] AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris] Obstetrical, Perinatal and Pediatric Epidemiology | Épidémiologie Obstétricale, Périnatale et Pédiatrique AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris] Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] AP-HP - Hôpital Antoine Béclère [Clamart] Service de Pédiatrie et Réanimations néonatales [Béclère] Hypertension pulmonaire : physiopathologie et innovation thérapeutique Physiopathologie des Adaptations Nutritionnelles Physiopathologie des Adaptations Nutritionnelles CHI Poissy-Saint-Germain Physiologie et physiopathologie endocriniennes CHI Poissy-Saint-Germain École Nationale Supérieure de Formation de l'Enseignement Agricole de Toulouse-Auzeville Education, Formation, Travail, Savoirs Hôpital Nord [CHU - APHM] Centre Hospitalier Universitaire d'Angers Centre Hospitalier Universitaire d'Angers CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier de Saint-Denis [Ile-de-France] Centre Hospitalier de Saint-Denis [Ile-de-France] Centre Hospitalier René Dubos [Pontoise] Hôpital Robert Debré Paris Centre de Recherche des Cordeliers Health data- and model- driven Knowledge Acquisition Centre d'Investigation Clinique 1426 Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables Maladies neurodéveloppementales et neurovasculaires CHU Amiens-Picardie Groupe de Recherche sur l'Analyse Multimodale de la Fonction Cérébrale - UMR INSERM_S 1105 UPJV Périnatalité et Risques Toxiques - UMR INERIS_I 1 UPJV Soins Intensifs de Néonatologie et Médecine Néonatale / Réanimation et Surveillance Continue de Pédiatrie [CHU Amiens]
• Publié dans The Lancet le 02/11/2020

---

Résumé : Background: Antenatal betamethasone is recommended before preterm delivery to accelerate fetal lung maturation. However, reports of growth and neurodevelopmental dose-related side-effects suggest that the current dose (12 mg plus 12 mg, 24 h apart) might be too high. We therefore investigated whether a half dose would be non-inferior to the current full dose for preventing respiratory distress syndrome. Methods: We designed a randomised, multicentre, double-blind, placebo-controlled, non-inferiority trial in 37 level 3 referral perinatal centres in France. Eligible participants were pregnant women aged 18 years or older with a singleton fetus at risk of preterm delivery and already treated with the first injection of antenatal betamethasone (11·4 mg) before 32 weeks' gestation. We used a computer-generated code producing permuted blocks of varying sizes to randomly assign (1:1) women to receive either a placebo (half-dose group) or a second 11·4 mg betamethasone injection (full-dose group) 24 h later. Randomisation was stratified by gestational age (before or after 28 weeks). Participants, clinicians, and study staff were masked to the treatment allocation. The primary outcome was the need for exogenous intratracheal surfactant within 48 h after birth. Non-inferiority would be shown if the higher limit of the 95% CI for the between-group difference between the half-dose and full-dose groups in the primary endpoint was less than 4 percentage points (corresponding to a maximum relative risk of 1·20). Four interim analyses monitoring the primary and the secondary safety outcomes were done during the study period, using a sequential data analysis method that provided futility and non-inferiority stopping rules and checked for type I and II errors. Interim analyses were done in the intention-to-treat population. This trial was registered with ClinicalTrials.gov, NCT02897076. Findings: Between Jan 2, 2017, and Oct 9, 2019, 3244 women were randomly assigned to the half-dose (n=1620 [49·9%]) or the full-dose group (n=1624 [50·1%]); 48 women withdrew consent, 30 fetuses were stillborn, 16 neonates were lost to follow-up, and 9 neonates died before evaluation, so that 3141 neonates remained for analysis. In the intention-to-treat analysis, the primary outcome occurred in 313 (20·0%) of 1567 neonates in the half-dose group and 276 (17·5%) of 1574 neonates in the full-dose group (risk difference 2·4%, 95% CI -0·3 to 5·2); thus non-inferiority was not shown. The per-protocol analysis also did not show non-inferiority (risk difference 2·2%, 95% CI -0·6 to 5·1). No between-group differences appeared in the rates of neonatal death, grade 3-4 intraventricular haemorrhage, stage ≥2 necrotising enterocolitis, severe retinopathy of prematurity, or bronchopulmonary dysplasia. Interpretation: Because non-inferiority of the half-dose compared with the full-dose regimen was not shown, our results do not support practice changes towards antenatal betamethasone dose reduction.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 17/08/2022
• Auteurs : Izanne RoosCharles MalpasEmmanuelle LerayRomain CaseyDana HorakovaEva Kubala HavrdovaMarc DebouverieFrancesco PattiJérôme de SèzeGuillermo IzquierdoSara EichauGilles EdanAlexandre PratMarc GirardSerkan OzakbasPierre GrammondHélène ZéphirJonathan CironElisabeth MaillartPamela Ann MccombeThibault MoreauMaria Pia AmatoPierre LabaugeBertrand BourreRaed AlroughaniKatherine BuzzardOlga SkibinaMurat TerziDavid-Axel LaplaudEric BergerMark SleeFrancois Grand'MaisonChristine Lebrun-FrénayElisabetta CartechiniAysun SoysalCavit BozJeannette Lechner-ScottPierre ClavelouBruno StankoffJulie Prévost-ZuddasLudwig KapposJean PelletierVahid ShaygannejadBassem YamoutSamia KhouryOliver GerlachDaniele SpitaleriVincent van PeschOlivier GoutRecai TurkogluOlivier HeinzlefEric ThouvenotTamara Castillo-TrivinoSerge BakchineRadek AmpapaErnest Gerard ButlerAbir WahabRichard MacdonellEduardo Aguera-MoralesPhilippe CabreNasr Haifa BenAnneke van der WaltGuy LaureysLiesbeth van HijfteCristina Ramo-TelloNicolas MaubeugeSuzanne HodgkinsonJosé Luis Sánchez-MenoyoMichael BarnettCeline LabeyrieSteve VucicYoussef SidhomRiadh GouiderTunde CsepanyJavier SotocaKoen de GansAbdullah Al-AsmiYara Dadalti FragosoSandra VukusicHelmut ButzkuevenTomas Kalincik
• Organismes : University of Melbourne Arènes: politique, santé publique, environnement, médias Recherche sur les services et le management en santé École des Hautes Études en Santé Publique Centre d'Investigation Clinique [Rennes] Recherche en Pharmaco-épidémiologie et Recours aux Soins Hospices Civils de Lyon Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Adaptation, mesure et évaluation en santé. Approches interdisciplinaires CIC Strasbourg Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre d'épidémiologie des populations Université de Montpellier CIC Plurithématique de Nantes Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Unité de Recherche Clinique Côte d’Azur Neuro-Dol Institut du Cerveau = Paris Brain Institute Hôpital de la Timone [CHU - APHM] Institut de Génomique Fonctionnelle Hospices Civils de Lyon Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center University of Melbourne
• Publié dans Neurology le 01/11/2020

---

Résumé : Background and objectives - To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. Methods - This was a retrospective cohort study from 2 large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12 months were included in the analysis. The primary study outcome was annualized relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation. Results - A total of 14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for 7 therapies. Annualized rates of relapse (ARRs) started to increase 2 months after natalizumab cessation (month 2-4 ARR 0.47, 95% CI 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89) and stabilized faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01 to 0.29). The magnitude of disease reactivation for other therapies was low but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were a higher relapse rate in the year before cessation, female sex, younger age, and higher EDSS score. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95% CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80). Discussion - The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued different therapies. These results suggest that untreated intervals should be minimized after stopping antitrafficking therapies (natalizumab and fingolimod). Classification of evidence - This study provides Class III that disease reactivation occurs within months of discontinuation of MS disease-modifying therapies. The risk of disease activity is reduced by commencement of a subsequent therapy.

---

Source

---

• Type de publi. : Pré-publication, Document de travail
• Date de publi. : 16/08/2022
• Auteurs : Jean-Michel LettDelphine MasséDenis FillouxThierry CandresseSébastien MassartArmelle MaraisEric VerdinNathalie CassamEmmanuel FernandezPhilippe RoumagnacPierre-Yves TeycheneyPierre Lefeuvre
• Organismes : Peuplements végétaux et bioagresseurs en milieu tropical Département Systèmes Biologiques Unité Ravageurs et agents pathogènes tropicaux Peuplements végétaux et bioagresseurs en milieu tropical Plant Health Institute of Montpellier Département Systèmes Biologiques Biologie du fruit et pathologie Unité de recherche TERRA [Gembloux] Biologie du fruit et pathologie Unité de Pathologie Végétale Unité Ravageurs et agents pathogènes tropicaux Plant Health Institute of Montpellier Département Systèmes Biologiques Plant Health Institute of Montpellier Département Systèmes Biologiques Peuplements végétaux et bioagresseurs en milieu tropical Département Systèmes Biologiques Peuplements végétaux et bioagresseurs en milieu tropical Département Systèmes Biologiques

---

Résumé : We report the complete genome sequencing of a novel member of the genus Vitivirus in the family Betaflexiviridae (subfamily Trivirinae) infecting pineapple. The full genome of this virus was obtained from total RNAs extracted from pineapple leaf samples collected in Reunion Island, using a combination of high-throughput sequencing technologies. It is 6,757 nt long, excluding the poly(A) tail, and shares all the hallmarks of vitiviruses. Phylogenetic analyses performed on the replication-associated protein and capsid protein gene sequences unambiguously place this new virus, for which we propose the name “pineapple vitivirus A”, in the Vitivirus genus.

---

Fichiers liés : 2022-Lett-Preprint-Research Square.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 16/08/2022
• Auteurs : François VergezLaetitia LargeaudSarah BertoliMarie-Laure NicolauJean-Baptiste RieuInès VergnolleEstelle SalandAudrey SarrySuzanne TavitianFrançoise HuguetMuriel PicardJean-Philippe VialNicolas LechevalierAudrey BidetPierre-Yves DumasArnaud PigneuxIsabelle LuquetVéronique Mansat-de MasEric DelabesseMartin CarrollGwenn Danet-DesnoyersJean-Emmanuel SarryChristian Récher
• Organismes : Centre de Recherches en Cancérologie de Toulouse
• Publié dans Blood Cancer Journal le 02/11/2020

---

Résumé : Abstract Classifications of acute myeloid leukemia (AML) patients rely on morphologic, cytogenetic, and molecular features. Here we have established a novel flow cytometry-based immunophenotypic stratification showing that AML blasts are blocked at specific stages of differentiation where features of normal myelopoiesis are preserved. Six stages of leukemia differentiation-arrest categories based on CD34, CD117, CD13, CD33, MPO, and HLA-DR expression were identified in two independent cohorts of 2087 and 1209 AML patients. Hematopoietic stem cell/multipotent progenitor-like AMLs display low proliferation rate, inv(3) or RUNX1 mutations, and high leukemic stem cell frequency as well as poor outcome, whereas granulocyte–monocyte progenitor-like AMLs have CEBPA mutations, RUNX1-RUNX1T1 or CBFB-MYH11 translocations, lower leukemic stem cell frequency, higher chemosensitivity, and better outcome. NPM1 mutations correlate with most mature stages of leukemia arrest together with TET2 or IDH mutations in granulocyte progenitors-like AML or with DNMT3A mutations in monocyte progenitors-like AML. Overall, we demonstrate that AML is arrested at specific stages of myeloid differentiation (SLA classification) that significantly correlate with AML genetic lesions, clinical presentation, stem cell properties, chemosensitivity, response to therapy, and outcome.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 15/08/2022
• Auteurs : Shengli TaoZurui AoWigneron J.-P.Sassan SaatchiPhilippe CiaisJérôme ChaveThuy Le ToanPierre-Louis FrisonXiaomei HuChi ChenLei FanMengjia WangJiangling ZhuXia ZhaoXiaojun LiXiangzhuo LiuYanjun SuTianyu HuQinghua GuoZhiheng WangZhiyao TangYi LiuJingyun Fang
• Organismes : Peking University [Beijing] Centre d'études spatiales de la biosphère South China Normal University [Guangdong, China] = Université normale de Chine du Sud [Canton, Chine] = 華南師范大學 Interactions Sol Plante Atmosphère Jet Propulsion Laboratory Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Evolution et Diversité Biologique Centre d'études spatiales de la biosphère Laboratoire en Sciences et Technologies de l'Information Géographique Centre d'études spatiales de la biosphère Peking University [Beijing] Lawrence Berkeley National Laboratory [Berkeley] Chongqing University [Chongqing] Zhengzhou University Peking University [Beijing] Chinese Academy of Sciences [Beijing] Chinese Academy of Sciences [Beijing] Interactions Sol Plante Atmosphère Chinese Academy of Sciences [Beijing] Chinese Academy of Sciences [Beijing] Peking University [Beijing] Peking University [Beijing] Peking University [Beijing] Interactions Sol Plante Atmosphère Peking University [Beijing]
• Publié dans Earth System Science Data le 23/10/2020

---

Résumé : Abstract. Satellite radar backscatter contains unique information on land surface moisture, vegetation features, and surface roughness, and can be acquired in all weather conditions, thus has been used in a range of earth science disciplines. However, there is no single global radar data set that spans more than two decades. This has limited the use of radar data for trend analysis over extended time intervals. We here provide the first long-term (since 1992), high resolution (~8.9 km) satellite radar backscatter data set over global land areas, the C-band Scatterometer (CScat) data set, by fusing signals from European Remote Sensing satellite (ERS, 1992–2001, C-band, 5.3 GHz), Quick Scatterometer (QSCAT, 1999–2009, Ku-band, 13.4 GHz), and the Advanced Scatterometer (ASCAT, since 2007, C-band, 5.255 GHz). The six-year data gap between C-band ERS and ASCAT was filled out by modelling an equivalent C-band signal during 1999–2009 from Ku-band QSCAT signals and climatic information. Towards this purpose, we first rescaled the signals from different sensors, pixel by pixel, using a new signal rescaling method that is robust to limited overlapping observations among sensors. We then corrected the monthly signal differences between the C-band and the scaled Ku-band signals, by modelling the signal differences from climatic variables (i.e., monthly precipitation, skin temperature, and snow depth) using decision tree regression. The quality of the merged radar signal was assessed by computing the Pearson r, Root Mean Square Error (RMSE), and relative RMSE (rRMSE) between the C-band and the corrected Ku-band signals in the overlapping years (1999–2001 and 2007–2009). We obtained high Pearson r values and low RMSE values at both the regional (r ≥ 0.93, RMSE ≤ 0.16, rRMSE ≤0.37) and pixel levels (median r across pixels ≥ 0.80, median RMSE ≤ 0.38, median rRMSE ≤ 0.64), suggesting high accuracy for the data merging procedure. The merged radar signal was then validated with a continuous ERS-2 data set available between 1995 and 2011. ERS-2 stopped working in full mode after 2001 but observations are occasionally available for a subset of the pixels until 2011. Because the period of 1995–2011 fully overlaps with the working period of QSCAT (1999–2009), comparing the merged radar signal against the ERS-2 data in 1995–2011 is the most direct validation available. We found concordant monthly dynamics between the merged radar signals and the ERS-2 signals during 1995–2011, with Pearson r value ranging from 0.79 to 0.98 across regions. These results evidenced that our merged radar data have a consistent C-band signal dynamic. The CScat data set (https://doi.org/10.6084/m9.figshare.20407857, Tao et al. 2022a) is expected to advance our understanding of the long-term changes in, e.g., global vegetation and soil moisture. The data set will be updated on a regular basis.

---

Fichiers liés : essd-2022-264.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 15/08/2022
• Auteurs : Delphine AvrilJean-Philippe FoyJebrane BouaoudVincent GrégoirePierre Saintigny
• Organismes : Centre de Recherche en Cancérologie de Lyon CHU Pitié-Salpêtrière [AP-HP] Centre de Recherche en Cancérologie de Lyon CHU Pitié-Salpêtrière [AP-HP] Centre de Recherche en Cancérologie de Lyon Centre Léon Bérard [Lyon] Université Claude Bernard Lyon 1 Centre Léon Bérard [Lyon] Centre de Recherche en Cancérologie de Lyon
• Publié dans International Journal of Radiation Biology le 31/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 11/08/2022
• Auteurs : Jonathan ChabertEtienne AllauzeBruno PereiraCarine ChassainIngrid de ChazeronJean-Yves RotgePhilippe FossatiPierre-Michel LlorcaLudovic Samalin
• Organismes : Service Psychiatrie Adulte [CHU Clermont-Ferrand] Institut Pascal Service Psychiatrie Adulte [CHU Clermont-Ferrand] Institut Pascal Direction de la Recherche Clinique et de l’Innovation [CHU Clermont-Ferrand] Service Imagerie Médicale et Radiologie Interventionnelle - site Gabriel-Montpied [CHU Clermont-Ferrand] Institut Pascal Service Psychiatrie Adulte [CHU Clermont-Ferrand] Institut Pascal Infrastructure de recherche clinique en psychiatrie adulte [ICM Paris] Infrastructure de recherche clinique en psychiatrie adulte [ICM Paris] Institut Pascal Pôle Psychiatrie Enfant-Adulte [CHU Clermont-Ferrand] Institut Pascal Pôle Psychiatrie Enfant-Adulte [CHU Clermont-Ferrand]
• Publié dans International Journal of Molecular Sciences le 03/05/2024

---

Résumé : The exact neurobiological mechanisms of bipolar disorder (BD) remain unknown. However, some neurometabolites could be implicated, including Glutamate (Glu), Glutamine (Gln), Glx, and N-acetylaspartate (NAA). Proton Magnetic Resonance Spectroscopy (1H-MRS) allows one to quantify these metabolites in the human brain. Thus, we conducted a systematic review and meta-analysis of the literature to compare their levels between BD patients and healthy controls (HC). The main inclusion criteria for inclusion were 1H-MRS studies comparing levels of Glu, Gln, Glx, and NAA in the prefrontal cortex (PFC), anterior cingulate cortex (ACC), and hippocampi between patients with BD in clinical remission or a major depressive episode and HC. Thirty-three studies were included. NAA levels were significantly lower in the left white matter PFC (wmPFC) of depressive and remitted BD patients compared to controls and were also significantly higher in the left dorsolateral PFC (dlPFC) of depressive BD patients compared to HC. Gln levels were significantly higher in the ACC of remitted BD patients compared to in HC. The decreased levels of NAA of BD patients may be related to the alterations in neuroplasticity and synaptic plasticity found in BD patients and may explain the deep white matter hyperintensities frequently observed via magnetic resonance imagery.

---

Fichiers liés : Glutamatergic and N-Acetylaspartate Metabolites in Bipolar Disorder= A Systematic Review and Meta-Analysis of Proton Magnetic Resonance Spectroscopy Studies.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 11/08/2022
• Auteurs : Richard EvershedGeorge Davey SmithMélanie Roffet-SalqueAdrian TimpsonYoan DiekmannMatthew LyonLucy CrampEmmanuelle CasanovaJessica SmythHelen WheltonJulie DunneVeronika BrychovaLucija ŠoberlPascale GerbaultRosalind E GillisVolker HeydEmily JohnsonIain KendallKatie ManningArkadiusz MarciniakAlan OutramJean-Denis VigneStephen ShennanAndrew BevanSue ColledgeLyndsay Allason-JonesLuc AmkreutzAlexandra AndersRose-Marie ArbogastAdrian BălăşescuEszter BánffyAlistair BarclayAnja BehrensPeter BoguckiÁngel Carrancho AlonsoJosé Miguel CarreteroNigel CavanaghErich ClaßenHipolito Collado GiraldoMatthias ConradPiroska CsengeriLech CzerniakMaciej DębiecAnthony DenaireLászló DomboróczkiChristina DonaldJulia EbertChristopher EvansMarta Francés-NegroDetlef GronenbornFabian HaackMatthias HalleCaroline HamonRoman HülshoffMichael IlettEneko IriarteJános JakucsChristian JeunesseMelanie JohnsonAndy JonesNecmi KarulDmytro KiosakNadezhda KotovaRüdiger KrauseSaskia KretschmerMarta KrügerPhilippe LefrancOlivia LelongEva LenneisAndrey LogvinFriedrich LüthTibor MartonJane MarleyRichard MortimerLuiz OosterbeekKrisztián OrossJuraj PavúkJoachim PechtlPierre PétrequinJoshua PollardRichard PollardDominic PowleslandJoanna PyzelPál RaczkyAndrew RichardsonPeter RoweStephen RowlandIan RowlandsonThomas SaileKatalin SebőkWolfram SchierGermo SchmalfußSvetlana SharapovaHelen SharpAlison SheridanIrina ShevninaIwona Sobkowiak-TabakaPeter StadlerHarald StäubleAstrid StobbeDarko StojanovskiNenad TasićIvo van WijkIvana VostrovskáJasna VukovićSabine WolframAndrea Zeeb-LanzMark Thomas
• Organismes : University of Bristol [Bristol] University of Bristol [Bristol] University of Bristol [Bristol] BioArchéologie, Interactions Sociétés Environnements University of Bristol [Bristol] Uniwersytet im. Adama Mickiewicza w Poznaniu = Adam Mickiewicz University in Poznań BioArchéologie, Interactions Sociétés Environnements Trajectoires - UMR 8215
• Publié dans Nature le 29/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 08/08/2022
• Auteurs : Chaithya Giliyar RadhakrishnaPierre WeissGuillaume Daval-FrérotAurélien MassireAlexandre VignaudPhilippe Ciuciu
• Organismes : Service NEUROSPIN Modèles et inférence pour les données de Neuroimagerie Institut de Mathématiques de Toulouse UMR5219 PRIMO (ITAV) Signal et Communications Unité de biologie Moléculaire, Cellulaire et du Développement Institut de recherche en informatique de Toulouse Centre de Biologie Intégrative Service NEUROSPIN Siemens Healthineers [Saint-Denis] Modèles et inférence pour les données de Neuroimagerie Siemens Healthineers [Saint-Denis] Building large instruments for neuroimaging: from population imaging to ultra-high magnetic fields Service NEUROSPIN Modèles et inférence pour les données de Neuroimagerie
• Publié dans IEEE Transactions on Medical Imaging le 26/10/2020

---

Résumé : The Spreading Projection Algorithm for Rapid K-space samplING, or SPARKLING, is an optimization-driven method that has been recently introduced for accelerated 2D T2*-w MRI using compressed sensing. It has then been extended to address 3D imaging using either stacks of 2D sampling patterns or a local 3D strategy that optimizes a single sampling trajectory at a time. 2D SPARKLING actually performs variable density sampling (VDS) along a prescribed target density while maximizing sampling efficiency and meeting the gradient-based hardware constraints. However, 3D SPARKLING has remained limited in terms of acceleration factors along the third dimension if one wants to preserve a peaky point spread function (PSF) and thus good image quality. In this paper, in order to achieve higher acceleration factors in 3D imaging while preserving image quality, we propose a new efficient algorithm that performs optimization on full 3D SPARKLING. The proposed implementation based on fast multipole methods (FMM) allows us to design sampling patterns with up to 10^7 k-space samples, thus opening the door to 3D VDS. We compare multi-CPU and GPU implementations and demonstrate that the latter is optimal for 3D imaging in the high-resolution acquisition regime (600µm isotropic). Finally, we show that this novel optimization for full 3D SPARKLING outperforms stacking strategies or 3D twisted projection imaging through retrospective and prospective studies on NIST phantom and in vivo brain scans at 3 Tesla. Overall the proposed method allows for 2.5-3.75x shorter scan times compared to GRAPPA-4 parallel imaging acquisition at 3 Tesla without compromising image quality.

---

Fichiers liés : 2020_Full3D_SPARKLING.pdf

---

Source